A Phase 3 interventional study of Travoprost ophthalmic solution, 0.003% and Travoprost ophthalmic solution, 0.004% in Open-Angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-18.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one has the largest enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 16 in phase 3, and was the 31st registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,099 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 3rd largest by enrollment of the 112 interventional ones that give a count, is one of 22 that started in 2011, is one of 43 in phase 3, and was the 78th registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.
This study consisted of six visits conducted during two sequential phases. The Screening/Eligibility phase included one screening visit and two eligibility visits. A washout period based on previous ocular medication preceded Eligibility Visit 1. Subjects who met all inclusion/exclusion criteria at both eligibility visits were randomized (1:1) at the second eligibility visit. The Treatment phase consisted of three on-therapy visits (Week 2, Week 6, and Month 3).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months
Drug: Travoprost ophthalmic solution, 0.003%
Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months
Drug: Travoprost ophthalmic solution, 0.004%
Also known as: TRAVATAN®
Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)
As measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye and only the study eye was used in the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
Time frame: Week 2, Week 6, Month 3 (8 AM, 10 AM, 4 PM)
Subjects were recruited from 60 investigational centers, including 52 in the US, 2 each in Sweden, Germany, and Austria, and 1 each in Spain and Finland.
| Milestone | Travoprost 0.003% | TRAVATAN |
|---|---|---|
| Started | 442 | 422 |
| Completed | 432 | 408 |
| Not completed | 10 | 14 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Patient decision unrel to adverse event | 3 | 3 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Inadequate control of iop | 1 | 5 |
| Withdrew: Other | 0 | 1 |
As measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye and only the study eye was used in the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
| millimeters mercury (mmHg) | Travoprost 0.003% | TRAVATAN |
|---|---|---|
| Week 2 at 8 AM | 19.4 ± 0.16 | 19.5 ± 0.17 |
| Week 2 at 10 AM | 18.6 ± 0.16 | 18.6 ± 0.16 |
| Week 2 at 4 PM | 18.0 ± 0.16 | 18.3 ± 0.16 |
| Week 6 at 8 AM | 19.3 ± 0.16 | 19.3 ± 0.17 |
| Week 6 at 10 AM | 18.5 ± 0.16 | 18.6 ± 0.17 |
| Week 6 at 4 PM | 18.0 ± 0.16 | 18.1 ± 0.17 |
| Month 3 at 8 AM | 19.2 ± 0.17 | 19.3 ± 0.18 |
| Month 3 at 10 AM | 18.3 ± 0.17 | 18.6 ± 0.18 |
| Month 3 at 4 PM | 18.0 ± 0.16 | 18.0 ± 0.17 |
Collected over Adverse events were collected from time of enrollment to study completion. An adverse event was considered to be any untoward medical occurrence in a patient exposed to the study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travoprost 0.003% | — | 5/442 (1.1%) | 56/442 (12.7%) |
| TRAVATAN | — | 7/421 (1.7%) | 64/421 (15.2%) |
| Event | Travoprost 0.003% | TRAVATAN |
|---|---|---|
| Chest PainGeneral disorders | 2/442 | 0/421 |
| CellulitisInfections and infestations | 0/442 | 1/421 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/442 | 1/421 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/442 | 1/421 |
| Drug hypersensitivityImmune system disorders | 0/442 | 1/421 |
| ErysipelasInfections and infestations | 0/442 | 1/421 |
| Myocardial infarctionCardiac disorders | 0/442 | 1/421 |
| NephrolithiasisRenal and urinary disorders | 0/442 | 1/421 |
| Abdominal painGastrointestinal disorders | 1/442 | 0/421 |
| Collapse of lungInjury, poisoning and procedural complications | 1/442 | 0/421 |
| Event | Travoprost 0.003% | TRAVATAN |
|---|---|---|
| Ocular hyperaemiaEye disorders | 31/442 | 34/421 |
| Conjunctival hyperaemiaEye disorders | 25/442 | 30/421 |
This reporting group includes subjects exposed to the study medication. Note: One subject in the TRAVATAN arm was randomized but discontinued prior to exposure to study medication and is not included in this reporting group.
| Age, Customized(Participants) | Travoprost 0.003% | TRAVATAN | Total |
|---|---|---|---|
| 18 to 64 years | 189 | 193 | 382 |
| ≥ 65 years | 253 | 228 | 481 |
| Sex: Female, Male(Participants) | Travoprost 0.003% | TRAVATAN | Total |
|---|---|---|---|
| Female | 269 | 246 | 515 |
| Male | 173 | 175 | 348 |
No study locations are listed for this record.
The record gives a start of Nov 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost